Switching from dupilumab to tralokinumab or Janus kinase inhibitors in cases of ocular and/or facial adverse events in patients with atopic dermatitis: a multicenter retrospective study

Update your browser to view ScienceDirect correctly.

Your technical details and browser version:

Request ID: 8f0fae3aece3cee1-LAX IP: 116.62.10.13 UTC time: 2024-12-12T18:12:05+00:00 Browser: Mozilla/5.0 (X11; U; Linux x86_64; en-US; rv:1.9.1.4) Gecko/20091030 Gentoo Firefox/3.5.4